Servier today announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) ...
News-Medical.Net on MSN
Atrial dysfunction assessment tool may help identify stroke risk in people with ATTR-CM
A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a non-invasive assessment tool may help identify those at increased risk, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback